PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD) This drug candidate hasdemonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] PKD is a life-changing disease affecting 1 in every 1,000 people[3] Half of the patient population withPKD will require a kidney transplant by the age of 60 due to the absence of impactful treatment options in this disease[4] PKD represents ...
Western Australia Crown Biosciences Human Genetics Research Drug Administration Polycystic Kidney Disease Webinar Friday
Source: singaporestar.com